2014, Number 07
PDF size: 390.87 Kb.
ABSTRACTBackground: The carcinosarcoma, or Mixed Mullerian Malign Tumors, represent 1% of malignant ovarian neoplasm, they are formed by a component epithelium and another mesenquimal malignant both.
Objective: Report the experience of the Ginecological Department of the Instituto Nacional de Cancerología (Mexico) in the treatment of patients with ovarian carcinosarcoma or primary malignant of the ovary.
Methods: A retrospective of 8 cases of carcinosarcoma primary of ovary at National Institute of Cancerology, from January, 2005 to December, 2008.
Results: The carcinosarcoma or Mixed Mullerian Malign Tumors appeared in 4.1 % of all the malignant primary tumors of ovary, the clinical initial presentation was with pain and abdominal expansion both in 62.5 % and mass palpable and bled vaginal in 25 % of the patients. In 2/8 (25%) patients there was achieved a residual tumor minor of 1cm, in 4/8 (50%) cases one administered chemotherapy. In 3/8 (37.5%) they were kept free of disease in the follow-up of 42 months, 1/8 (12.5%) with stable disease and 4/8 (50%) they died for disease.
Conclusions: Ovarian carcinosarcoma is a rare tumor, the clinical of this neoplasm is aggressive, usually presenting in advanced stages, with a poor prognosis with existing medical treatment.
Varras M, Akrivis Ch, Antoniou N, Tolis C, Stefanaki S, Salamalekis E. Primary Ovarian Carcinosarcoma: A Case Report and Review of the Literature. Eur J Gynaecol Oncol 2004;25:653-656.
Morrow CP, d’Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. Clinical and Pathologic Study of 30 cases of Malignant Mixed Epithelial and Mesenchymal Ovarian Tumors: A Gynecologic Oncology Group Study. Gynecologic Oncology 1984;18:278-292.
Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, et al. Primary Ovarian Sarcoma. Analysis of Prognostic Variables and the Role of Surgical Cytoreduction. Cancer 1998;2:1731-1737.
Le T, Krepart GV, Lotocki RJ, Heywood MS. Malignant Mixed Mesodermal Ovarian Tumor Treatment and Prognosis: A 20 year experience. Gynecology Oncology 1997;65:237-240.
Ariyoshi K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic Factors in Ovarian Carcinosarcoma: A Clinico- Pathological and Inmunohistochemical Analysis of 23 cases. Histopathology 2000;37:427-436.
Fowler JM, Nathan L, Nieberg RK, Berek JS. Case Report: Mixed Mesodermal Sarcoma of the Ovary in a Young Patient. Eur Journal of Obstetrics & Ginecology and Reproductive Biology 1996;65:249-253.
Wei LH, Huang CY, Cheng SP, Chen CA, Hsieh CY. Carcinosarcoma of Ovary associated with previous radiotherapy. Int J Gynecol 2001;11:81-84.
Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D’Hondt V, et al. Current Management of Ovarian Carcinosarcoma. Int Gynecol Cancer 2007;17:316-324.
Chang J, Sharpe JC, A’Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the Ovary: Incidence, Prognosis, Treatment and Survival of patients. Ann Oncol 1995;6:755- 763.
Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, et al. Clinical Features and Outcome of Uterine and Ovarian Carcinosarcoma. Gynecol Oncol 2006;100:561- 564.
Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the Ovary Treated with Platinum and Taxane: The Memorial Sloan Kettering Cancer Center Experience. Gynecology Oncology 2007;105:657-661.
Silasi DA, Illuzzi JL, Kelly MG, Rutherford TJ, Mor G, Azodi M, et al. Carcinosarcoma de Ovary. Int J Gynecol Cancer 2008;18:22-29.
Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and Platinum Chemotherapy for Malignant Mixed Mullerian Tumors of the Ovary. Ginecologic Oncology 2002;85:459-463.
Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, et al. Ovarian Carcinosarcomas: Clinico-pathological Prognostic Factors and Evaluation of Chemotherapy Regimens Containing Platinum. Gynecologic Oncology 2008;108:136- 140.
Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, et al. Carcinosarcoma on the Ovary. British Journal of Cancer 2003;88:654-657.
Zorzou MP, Markaki S, Rodolakis A, Kastritis E, Bozas G, Dimopoulos MA, et al. Clinico-pathological Features of Ovarian Carcinosarcomas: A Single Institution Experience. Gynecologic Oncology 2005;96:136-142.
Athavale R, Thomakos N, Godfrey K, Kew F, Cross P, de Barros Lopes A, et al. The Effect of the Epithelial and Stromal Tumors Components on FIGO Stage III and IV Ovarian Carcinosarcomas Treated with Primary Surgery and Chemotherapy. Int J Gynecol Cancer 2007;17:1025-1030.
Sonoda Y, Saigo P, Federici M, Boyd J. Carcinosarcoma of the Ovary in a Patient with Germline BRCA 2 Mutation: Evidence for Monoclonal Origin. Gynecologic Oncology 2000;76:226-229.
Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al. Carcinosarcoma of the Ovary- A Case Series. Gynecologic Oncology 2006;100:128-132.
Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as Initial Chemotherapy in Ovarian Carcinosarcomas: A Gynecologic Oncology Group Study. Gynecology Oncology 2004;93:336-339.
Melilli GA, Di Vagno G, Cormio G, Greco P, Fontana A, Carriero C, et al. Chemotherapy in the Treatment of Ovarian Carcinosarcoma. Minerva Ginecol 1990;51:445-448.
Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, et al. Carcinosarcoma of the Ovary 19 years. Prospective Data from a Single Center 2004;100:2148- 2153.
Xanthoulis A, Mirelis C, Markakidis S, Bougioukas I, Bekiaridou K, Tsalkidou E, et al. Complete Cytoreduction combined with early post-operative Intra-peritoneal chemotherapy for ovarian carcinosarcoma. Report of Two Cases. Gynecol Obstet Invest 2006;62:100-102.
Intrasorn P, Beale P, Dalrymple C, Carter J. Malignant Mixed Mullerian Tumour of the Ovary: Prognostic Factor and Response of Adjuvant Platinum-Based Chemotherapy. Aust. NZJ Obstet Gyneacol 2003;43:61-64.